{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:38:33Z","timestamp":1790721513293,"version":"4.1.0"},"reference-count":46,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"10","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2022,10,27]]},"DOI":"10.1167\/tvst.11.10.37","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:32:28Z","timestamp":1666884748000},"page":"37","source":"Crossref","is-referenced-by-count":25,"title":["Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies"],"prefix":"10.1167","volume":"11","author":[{"given":"David D.","family":"Boyer","sequence":"first","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ping","family":"Ko","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Podos","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Wiles","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Huang","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/bjophthalmol-2015-306972","article-title":"Current therapeutic developments in atrophic age-related macular degeneration","volume":"100","author":"Hanus","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial","volume":"309","author":"Age-Related Eye Disease Study 2 Research Group","year":"2013","journal-title":"JAMA"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11095-018-2498-y","article-title":"Targeted ocular drug delivery with pharmacokinetic\/pharmacodynamic considerations","volume":"35","author":"Shen","year":"2018","journal-title":"Pharm Res"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/DMSO","article-title":"Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia","volume":"12","author":"Spooner","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.oret.2021.04.001","article-title":"Evolving treatment patterns and outcomes of neovascular age-related macular degeneration over a decade","volume":"5","author":"Schwartz","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"bib13","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","article-title":"Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Risitano","year":"2021","journal-title":"Haematologica"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2016.153312","article-title":"Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"102","author":"Yuan","year":"2017","journal-title":"Haematologica"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.2174\/0929867326666191001130342","article-title":"Discovery and development of the oral complement factor D inhibitor danicopan (ACH-4471)","volume":"27","author":"Wiles","year":"2020","journal-title":"Curr Med Chem"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/pcr.1999.12.issue-4","article-title":"Current understanding on the role of retinal pigment epithelium and its pigmentation","volume":"12","author":"Schraermeyer","year":"1999","journal-title":"Pigment Cell Res"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1562\/2004-10-19-RA-345.1","article-title":"Comparisons of the structural and chemical properties of melanosomes isolated from retinal pigment epithelium, iris and choroid of newborn and mature bovine eyes","volume":"81","author":"Liu","year":"2005","journal-title":"Photochem Photobiol"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2017.12.008","article-title":"Implications of melanin binding in ocular drug delivery","volume":"126","author":"Rimpela","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1167\/iovs.12-10169","article-title":"Assessing a novel depot delivery strategy for noninvasive administration of VEGF\/PDGF RTK inhibitors for ocular neovascular disease","volume":"54","author":"Robbie","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1006\/rtph.2000.1380","article-title":"Technical validation of radioluminography systems","volume":"31","author":"Kolbe","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1056-8719(02)00162-4","article-title":"Methods determining phosphor imaging limits of quantitation in whole-body autoradiography rodent tissue distribution studies affect predictions of 14C human dosimetry","volume":"46","author":"Solon","year":"2001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3109\/03602538409033561","article-title":"The melanin binding of drugs and its implications","volume":"15","author":"Ings","year":"1984","journal-title":"Drug Metab Rev"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1023\/A:1015997823755","article-title":"Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses","volume":"7","author":"Zane","year":"1990","journal-title":"Pharm Res"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/2271257a0","article-title":"Accumulation of chorio-retinotoxic drugs in the foetal eye","volume":"227","author":"Ullberg","year":"1970","journal-title":"Nature"},{"key":"bib27","first-page":"405","article-title":"The reaction of uveal pigment in vitro with polycyclic compounds","volume":"3","author":"Potts","year":"1964","journal-title":"Invest Ophthalmol"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejps.2017.07.027","article-title":"Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts","volume":"109","author":"Pelkonen","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jconrel.2018.05.034","article-title":"Melanin targeting for intracellular drug delivery: quantification of bound and free drug in retinal pigment epithelial cells","volume":"283","author":"Rimpela","year":"2018","journal-title":"J Control Release"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/aos.v97.s263","article-title":"Ocular melanin binding of drugs: in vitro binding studies","volume":"97","author":"Bahrpeyma","year":"2019","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"10106","DOI":"10.1021\/acs.jmedchem.8b01281","article-title":"Understanding molecular drivers of melanin binding to support rational design of small molecule ophthalmic drugs","volume":"61","author":"Jakubiak","year":"2018","journal-title":"J Med Chem"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1021\/acs.molpharmaceut.9b00769","article-title":"Establishment of an in vitro\u2013in vivo correlation for melanin binding and the extension of the ocular half-life of small-molecule drugs","volume":"16","author":"Jakubiak","year":"2019","journal-title":"Mol Pharm"},{"key":"bib34","first-page":"833","article-title":"Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: results from the phase 3 DERBY and OAKS trials","volume":"49","author":"Guymer","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"eaaf1443","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci Transl Med"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","article-title":"Complement cascade inhibition in geographic atrophy: a review","volume":"36","author":"Desai","year":"2022","journal-title":"Eye (Lond)"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Penetration of bevacizumab through the retina after intravitreal injection in the monkey","volume":"48","author":"Heiduschka","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","article-title":"Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes","volume":"98","author":"Julien","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.7.26","article-title":"Differential and altered spatial distribution of complement expression in age-related macular degeneration","volume":"62","author":"Demirs","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/9783527636150.ch6","article-title":"Structure of melanins","volume-title":"Melanins and Melanosomes: Biosynthesis, Biogenesis, Physiological, and Pathological Functions","author":"Ito","year":"2011"},{"key":"bib23","first-page":"251","volume-title":"Ocular Transporters and Receptors: Their Role in Drug Delivery","author":"Mitra","year":"2013"},{"key":"bib39","article-title":"Intravitreal LFG316 in patients with age-related macular degeneration (AMD)","author":"ClinicalTrials.gov"},{"key":"bib40","article-title":"CLG561 proof-of-concept study as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (GA)","author":"ClinicalTrials.gov"},{"key":"bib41","article-title":"A phase 3 safety and efficacy study of intravitreal administration of Zimura (complement C5 inhibitor)","author":"ClinicalTrials.gov"},{"key":"bib42","article-title":"A study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration","author":"ClinicalTrials.gov"},{"key":"bib43","article-title":"Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration","author":"ClinicalTrials.gov"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2783791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:32:35Z","timestamp":1666884755000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2783791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.11.10.37","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}